Personalis, Inc., (Nasdaq: PSNL) a leader in advanced genomics for cancer, today announced the appointment of Leslie Grab as VP of Intellectual Property and John Lyle as VP of Assay Research and Development.
Dr. Grab joins Personalis from Verily Life Sciences (a Google spin-out), where she was responsible for worldwide patent & trademark strategy and portfolio development across multiple product areas. Prior to that, Dr. Grab worked at the law firm of Kilpatrick Townsend & Stockton, where she focused on patent prosecution, technology transactions, and patent litigation in the fields of chemistry, biochemistry, molecular biology, and medical diagnostics. Dr. Grab holds a PhD in Biochemistry and Molecular Biology from Wake Forest University and a BA in Chemistry from Catawba College, North Carolina. She earned her law degree from the University of North Carolina, Chapel Hill, where she also served as a Post-Doctoral Associate researching the inter-relationship between exosomes and ovarian cancer.
Dr. Lyle joins Personalis after 14 years at Pacific Biosciences (NASDAQ: PACB), where he most recently served as Senior Director of Single Molecule Sequencing focusing on reagent, system, and application development of long-read, ultra-high accuracy sequencing. Dr. Lyle received his PhD from Stanford University in Microbiology and Immunology and holds a BS from Bates College, Maine. Dr. Lyle also served as a Post-Doctoral Fellow at the University of California, San Francisco, studying the structure and function of the centrosome.
"We’re very pleased to have such experienced professionals join our management team here at Personalis," said John West, Personalis CEO. "The life sciences experience that both Drs. Grab and Lyle bring to the organization will assist us to continue our history of developing innovative and proprietary genomics solutions to address the needs of our pharmaceutical and institutional partners across the globe."
About Personalis, Inc.
Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The Personalis® ImmunoID NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. Personalis also provides genomic information to the VA Million Veterans Program as part of their goal to sequence over a million veteran genomes. The Personalis Clinical Laboratory is GxP-aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).
This press release contains or may imply "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include all statements that are not historical facts, including, for example, statements relating to the potential advancement of or growth opportunities for Personalis’ business, expansion of Personalis’ market presence in immuno-oncology, the company’s services for the VA Million Veterans Program, and other future events. These forward-looking statements are subject to risks and uncertainties, including those related to the evolution of cancer therapies and market adoption of our services, our expectations regarding future performance, and the COVID-19 pandemic, as well as other risks and uncertainties discussed in Personalis’ filings with the Securities and Exchange Commission (SEC), including in the "Risk Factors" and "Management’s Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company’s most recently filed periodic reports on Forms 10-K and 10-Q and subsequent filings and in the documents incorporated by reference therein, all of which may significantly impact our business and operations, the business and operations of our customers, our ability to access capital and the value of our common stock. Except as otherwise required by law, Personalis disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.